What question did this study set out to answer?

To explore a potential mechanism by which aluminum adjuvant nanoparticles may enter the central nervous system via polysorbate 80.

February 27, 2026Open Access

Polysorbate 80 as a Potential Vector for Vaccine Aluminum Adjuvant Nanoparticles into the Central Nervous System via Apolipoprotein Adsorption: An Uninvestigated Hypothesis

Key Points

To explore a potential mechanism by which aluminum adjuvant nanoparticles may enter the central nervous system via polysorbate 80.
Reviewed existing literature on polysorbate 80, aluminum adjuvants, and their interaction mechanisms.
Discussed Kreuter's drug delivery mechanism and Gherardi's biopersistence findings.
Highlighted aluminum accumulation evidence from studies on autism brain tissue.
Aluminum adjuvant nanoparticles may form complexes with polysorbate 80 that adsorb apolipoproteins.
These complexes could potentially cross the blood-brain barrier through receptor-mediated transport.
Evidence suggests long-term aluminum biopersistence in the brain, especially in individuals with autism.

Abstract

A convergence of Kreuter's drug delivery mechanism, Gherardi's adjuvant biopersistence research, and Exley's findings of aluminum accumulation in autism brain tissue Abstract Background: Several widely used vaccine formulations simultaneously contain aluminum salts as adjuvants andpolysorbate 80 (PS80) as a surfactant. The pharmacological properties of each excipient have been independentlydocumented in the literature, yet their potential synergistic interaction has never been experimentally evaluated. Hypothesis: We propose that aluminum adjuvant nanoparticles present in vaccine formulations containing PS80may adsorb this surfactant onto their surface following injection. The resulting Al-PS80 complex may adsorbcirculating apolipoproteins — primarily ApoE and ApoB — and subsequently be transported into the brainparenchyma via receptor-mediated transcytosis across the blood-brain barrier (BBB), by the mechanism described byKreuter et al. for PS80-coated polymeric nanoparticles. Evidence base: Three independent lines of research support the biological plausibility of this hypothesis: (1) Kreuteret al. demonstrated that PS80-coated nanoparticles of diverse chemical composition adsorb apolipoproteins in vivo,enabling LDL receptor-mediated endocytosis at the cerebrovascular endothelium; (2) Gherardi et al. demonstratedthat vaccine aluminum particles exhibit long-term biopersistence and can translocate to the brain via intracellularphagocyte-mediated transport; (3) Mold, Umar, King and Exley (2018) reported some of the highest aluminumconcentrations ever measured in human brain tissue in donors with autism spectrum disorder, with aluminum foundpredominantly in microglia-like and non-neuronal inflammatory cells — a pattern consistent withphagocyte-mediated transport. The coexistence of both excipients in the same formulation — documented in Prevnar13/20, Gardasil 9, and several combined pediatric vaccines — creates conditions for the proposed interaction. Implications: If confirmed, this mechanism would represent an additional pathway for aluminum adjuvantneurodeposition, with particular relevance for infants receiving multiple doses of aluminum- and PS80-containingvaccines during the window of BBB maturation. A structurally analogous parallel hypothesis is articulated regardingPEGylated lipid nanoparticles (LNPs) in mRNA vaccines. Both hypotheses are falsifiable and amenable to directexperimental testing

KI fragen

Bookmark

View Full Paper